<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN">
<html>
<head>
<meta http-equiv="Content-Type" content="text/html; charset=windows-1251">
<title>Страчунский Л.С., Козлов С.Н. Макролиды в современной клинической практике</title>
<meta name="description" content="Страчунский Л.С., Козлов С.Н. Макролиды в современной клинической практике">
<meta name="keywords" content="">
<link rel="StyleSheet" type="text/css" href="include/mcl.css">
<style type="text/css">
P	{text-align: justify;}
OL {margin-left: 25px; text-align: justify;}
LI {margin-top: 10px; margin-bottom: 1px; margin-left: 15px;}
</style>
</head>

<body class="main">

<h3>СПИСОК ЛИТЕРАТУРЫ</h3>

<ol>
<a name="1"></a><li value="1">Mazzei Т., Mini E., Novelli A., et&nbsp;al. Chemistry and mode of action of macrolides. J.&nbsp;Antimicrob. Chemother., 1993, 31 (suppl.&nbsp;С):&nbsp;1-9.</li>
<a name="2"></a><li value="2">Vanuffel P., Cocito С. Mechanism of action of streptogramins and macrolides. Drugs, 1996, 51 (suppl.&nbsp;1): 20-30.</li>
<a name="3"></a><li value="3">Di Giambattista M., Nyssen E., Engelborghs Y., et&nbsp;al. Kinetics of binding of macrolides, lincosamides and synergimycins to ribosomes. J.&nbsp;Biol. Med., 1987, 262:&nbsp;8591-8597.</li>
<a name="4"></a><li value="4">Smilack J.D., Wilson W.R., Cockerill III F.R. Tetracyclins, chloramphenicol, erythromycin, clindamycin, and metronidazol. Mayo Clin. Proc., 1991, 66:&nbsp;1270-1280.</li>
<a name="5"></a><li value="5">Labro M.T. Pharmacology of spiramycin. Drug Invest., 1993, 6 (suppl.&nbsp;1): 15-28.</li>
<a name="6"></a><li value="6">Neu H.C. Bacterial resistance to other agents. In: Antibiotics in Laboratory Medicine. Lorian V. (Ed.). 3rd ed. Baltimore etc., 1991: 714-722.</li>
<a name="7"></a><li value="7">Periti P., Mazzei Т., Mini E., et al. Clinical pharmacokinetic properties of the macrolide antibiotics. Effects of age and various pathphysiological states (part I). Clin. Pharmacokinet., 1989, 16: 193-214.</li>
<a name="8"></a><li value="8">Bolmstrom A., Esberg К., Wiman A., et al. Effects of CO<sub>2</sub> incubation on macrolides. In: The 36th International Conference on Antimicrobial Agents and Chemotherapy. New Orleans, 1996: abstr. D38.</li>
<a name="9"></a><li value="9">Kenny G.E., Cartwright F.D. Effect of рН on killing of <i>Mycoplasma pneumoniae</i> by azithromycin. In: The 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. New Orleans, 1996: abstr. E69.</li>
<a name="10"></a><li value="10">Pontani D. Comparison of CO<sub>2</sub> effect within different testing methodologies on azithromycin MIC levels for <i>Streptococcus pneumoniae</i> and <i>Streptococcus pyogenes</i> isolated in a multicenter, multinational surveillance study. In: The 20th International Congress of Chemotherapy. Sydney, 1997: abstr. 4205.</li>
<a name="11"></a><li value="11">Tanaka S.K., Jones R.N., Lartey P. New and &quot;unusual&quot; antimicrobial properties of clarithromycin. In: New Macrolides, Azalides, and Streptogramins in Clinical Practice. Neu&nbsp;H.C., Young&nbsp;L.S., Zinner&nbsp;S.H., Acar&nbsp;J.F. (Eds.). New York, etc., 1995: 225-230.</li>
<a name="12"></a><li value="12">National Committee for Clinical Laboratory Standards: Performance Standards for Antimicrobial Disk Susceptibility Tests for Bacteria that Grow Aerobically, Sixth Edition; Approved Standard NCCLS. Document M2-A6, 1997,17:&nbsp;1.</li>
<a name="13"></a><li value="13">Woods G.L., Washington J.A. Antibacterial Susceptibility Tests:
Dilution and Disk Diffusion Methods. In: Manual of Clinical Microbiology. Murray&nbsp;P., et al. (Eds.), 6th ed. Washington, 1995: 1327-1341.</li>
<a name="14"></a><li value="14">Jorgensen J.H., Sahm D.F. Antimicrobial Susceptibility Testing:
General Considerations. In: Manual of Clinical Microbiology. Murray&nbsp;P., et al. 6th ed. Washington. 1995: 1277-1280.</li>
<a name="15"></a><li value="15">Acar J.F., Goldstein F.W. Disk Susceptibility Test. In: Antibiotics in Laboratory Medicine. Lorian&nbsp;V. (Ed.). Baltimore etc., 1996: 1-51.</li>
<a name="16"></a><li value="16">Ericsson H.M., Sherris J.C. Antibiotic Sensitivity Testing. Report of an International Collaborative Study. Acta Pathol. Microbiol. Scand., 1971, 217 (suppl.&nbsp;В): 1-90.</li>
<a name="17"></a><li value="17">Fiese E.F., Steffen S. Comparison of the acid stability of azithromycin and erythromycin. J.&nbsp;Antimicrob. Chemother., 1990, 25 (suppl.&nbsp;A): 39-47.</li>
<a name="18"></a><li value="18">Retsema J.A., Brennan L.A., Girard A.E. Effects of the environmental factors on the <i>in&nbsp;vitro</i> potency of azithromycin. Eur. J.&nbsp;Clin. Microbiol. Infect. Dis., 1991, 10: 834-842.</li>
<a name="19"></a><li value="19">Hardy D.J., Hensey D.M., Beyer J.M., et al. Comparative <i>in&nbsp;vitro</i> activities of new 14-, 15- and 16-membered macrolides. Antimicrob. Agents Chemother., 1988, 32: 1710-1719.</li>
<a name="20"></a><li value="20">Wanger A., Mills К., Wiman A., Bolmstrom A. Effect of CO<sub>2</sub> on Erythromycin MICs of <i>Streptococcus pneumoniae</i>. In: The 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, 1995: abstr. El46.</li>
<a name="21"></a><li value="21">Dabernat H., De Pina Т., Derrienning M., et al. Influence of medium and culture conditions on susceptibility of <i>Haemophilus influenzae</i> to dirithromycin. Comparison with Erythromycin. In: The 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. San&nbsp;Francisco, 1995: abstr. D16.</li>
<a name="22"></a><li value="22">Crokaert F., Aoun M., Duchateau V., et al. Are macrolides active against <i>Haemophilus influenzae</i>? Are the <i>in&nbsp;vitro</i> tests reliable? In: The 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. San&nbsp;Francisco, 1995: abstr. D15.</li>
<a name="23"></a><li value="23">Методические указания по определению чувствительности микроорганизмов к антибиотикам методом диффузии в агар с использованием дисков. - Министерство здравоохранения СССР, 1983.</li>
<a name="24"></a><li value="24">Leclerq R., Courvalin P. Resistance to macrolides, azalides, and streptogramins. In: New Macrolides, Azalides, and Streptogramins in Clinical Practice. Neu&nbsp;H.C., Young&nbsp;L.S., Zinner&nbsp;S.H., Acar&nbsp;J.F. (Eds.). New&nbsp;York, etc., 1995: 31-40.</li>
<a name="25"></a><li value="25">Williams J.D., Sefton A.M. Comparison of macrolide antibiotics. J.&nbsp;Antimicrob. Chemother., 1993, 31 (suppl.&nbsp;С): 11-26.</li>
<a name="26"></a><li value="26">Bauernfeind A. <i>In vitro</i> activity of dirithromycin in comparison with other new and established macrolides. J.&nbsp;Antimicrob. Chemother., 1993, 31 .(suppl.&nbsp;С): 39-49.</li>
<a name="27"></a><li value="27">Derriennic M., Escande J.P. Dirithromycin in the treatment of skin and skin structure infections. J.&nbsp;Antimicrob. Chemother., 1993, 31 (suppl.&nbsp;С):159-168.</li>
<a name="28"></a><li value="28">Ruggiero G., Utili R., Adinolfi L.E., et al. Clinical efficacy of dirithromycin versus miocamycin in tonsillopharyngitis. J.&nbsp;Antimicrob. Chemother., 1993, 31 (suppl.&nbsp;С): 103-109.</li>
<a name="29"></a><li value="29">Klugman К., Moser W. MIC-testing of 40 multi-resistant (erythromycin and penicillin) strains of <i>Streptococcus pneumoniae</i> and 40 erythromycin-resistant <i>Streptococcus pyogenes</i> isolates against 6 different macrolides. In; The 3rd International Conference on the Macrolides, Azalides and Streptogramins. Lisbon, 1996: abstr. 3.01.</li>
<a name="30"></a><li value="30">Alcaide F., Carratal J., Liyares J., et al. <i>In&nbsp;vitro</i> activity of eight macrolide antibiotics and RP-59500 against viridans streptococci isolated from blood of neutropenic cancer patients. In: The 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. 1995: abstr. E51.</li>
<a name="31"></a><li value="31">Desnottes J.F. New aspects of spiramycin&rsquo;s effect on bacteria - host cell interactions. In: Predicting Antibiotic Response in Respiratory Tract Infections. Highlights from the 7th International Congress for Infectious Diseases. Hong&nbsp;Kong, 1996: 4-6.</li>
<a name="32"></a><li value="32">Endtz H.P., Broeren M., Mouton R.P. <i>In&nbsp;vitro</i> susceptibility of quinolone-resistant <i>Campylobacter&nbsp;jejuni</i> to new macrolide antibiotics. Eur. J.&nbsp;Clin. Microbiol. Infect. Dis., 1993, 12: 48-50.</li>
<a name="33"></a><li value="33">Liebers D.M., Baltch A.L., Smith R.P., et al. Susceptibility of <i>Legionella pneumophila</i> to eight antimicrobial agents including four macrolides under different assay conditions. J.&nbsp;Antimicrob. Chemother., 1989, 23: 37-41.</li>
<a name="34"></a><li value="34">Goddard A.F., Logan R.P.H. Antimicrobial resistance and <i>Helicobacter&nbsp;pylori</i>. J.&nbsp;Antimicrob. Chemother., 1996, 37: 639-643.</li>
<a name="35"></a><li value="35">Ridgway G.L. Chlamydia and other sexually transmitted diseases. In:
New Macrolides, Azalides, and Streptogramins in Clinical Practice. Neu&nbsp;H.C., Young&nbsp;L.S., Zinner&nbsp;S.H., Acar&nbsp;J.F. (Eds.). New&nbsp;York, etc., 1995: 147-154.
</li>
<a name="36"></a><li value="36">Gialdroni Grassi G., Grassi C. Clinical application of macrolides and azalides in <i>Legionella, Mycoplasma</i>, and <i>Chlamydia</i> respiratory infections. In: New Macrolides, Azalides, and Streptogramins in Clinical Practice. Neu&nbsp;H.C., Young&nbsp;L.S., Zinner&nbsp;S.H., Acar&nbsp;J.F. (Eds.). New&nbsp;York, etc., 1995: 95-119.</li>
<a name="37"></a><li value="37">Chang H.R., Pechere J.C. <i>In&nbsp;vitro</i> effects of four macrolides (roxithromycin, spiramycin, azithromycin [CP-62993] and A-56268) on <i>Toxoplasma gondii</i>. Antimicrob. Agents Chemother., 1988, 35: 524-529.</li>
<a name="38"></a><li value="38">Huskinson-Mark J., Araujo F.G., Remington J.S. Evaluation of the effect of drugs on the cyst form of <i>Toxoplasma gondii</i>. J. Infect. Dis., 1991, 164: 170-177.</li>
<a name="39"></a><li value="39">Ridgway G.L. The <i>in vitro</i> activity of macrolides, azalides and streptogramins against <i>Mycoplasma</i> spp. and intracellular organisms. In: The 1st International Conference on the Macrolides, Azalides and Streptogramines. Santa&nbsp;Fe, 1992: abstr. 3.</li>
<a name="40"></a><li value="40">Naik S., Ruck R. <i>In&nbsp;vitro</i> activities of several new macrolide antibiotics against <i>Mycobacterium avium</i> complex. Antimicrob. Agents Chemother., 1989, 33: 1614-1616.</li>
<a name="41"></a><li value="41">Piscitelli S.C., Danziger L.H., Rodvold K.A. Clarithromycin and azithromycin; new macrolide antibiotics. Clin. Pharmacol., 1992, 11: 137-152.</li>
<a name="42"></a><li value="42">Luft B.J., Bosler E.M. Treatment of early Lyme borreliosis with macrolide antibiotics. In; New Macrolides, Azalides, and Streptogramins in Clinical Practice. Neu&nbsp;H.C., Young&nbsp;L.S., Zinner&nbsp;S.H., Acar&nbsp;J.F. (Eds.). New&nbsp;York, etc., 1995: 141-145.</li>
<a name="43"></a><li value="43">Sturgill M.G., Rapp R.P. Clarithromycin: a review of a new macrolide antibiotic with improved microbiologic spectrum and favorable pharmacokinetic and adverse event profiles. Ann. Pharmacother., 1992, 26: 1099-1108.</li>
<a name="44"></a><li value="44">Drew R.H., Gallis H.A. Azithromycin - spectrum of activity, pharmacokinetics and clinical applications. Pharmacotherapy, 1992, 12: 161-173.</li>
<a name="45"></a><li value="45">Kamimiya S., Weisblum B. Induction of ermCV by 16-memberedring macrolide antibiotics. Antimicrob. Agents Chemother., 1997, 41: 530-534.</li>
<a name="46"></a><li value="46">Steigbigel N.H. Macrolides and clindamycin. In: Princeples and Practice of Infectious Diseases. 4th ed. Mandell&nbsp;G.L., Bennett&nbsp;J.E., Dolin&nbsp;R. (Eds.). New&nbsp;York, etc., 1995: 334-346.</li>
<a name="47"></a><li value="47">Bermudez L.E., Petrofsky M., Kolonsky P., et al. Emergence of <i>Mycobacterium&nbsp;avium</i> population resistant to macrolides during experimental chemotherapy. In: The 36th International Conference on Antimicrobial Agents and Chemotherapy. New&nbsp;Orleans, 1996: abstr. C145.</li>
<a name="48"></a><li value="48">Nightingale C.H., Nicolau D., Vanhove G.F., et al. Bronchopulmonary concentrations of Clarithromycin once-daily vs. azithromycin once-daily. In: The 20th International Congress of Chemotherapy. Abstracts of symposium Innovations in Macrolide Therapy. Sydney, 1997:&nbsp;6.</li>
<a name="49"></a><li value="49">Hyatt J.M., Schentag J.J. Relative potential for selection for resistant <i>Streptococcus&nbsp;pneumoniae</i> from previously susceptible strains following exposure to azithromycin, ampicillin or cefaclor. In: The 36th Conference on Antimicrobial Agents and Chemotherapy. New Orleans, 1996: abstr. C110.</li>
<a name="50"></a><li value="50">Ridley M., Lynn R., Barrie D., et al. Antibiotic-resistant <i>Staphylococcus&nbsp;aureus</i> and hospital antibiotic policies. Lancet, 1970, 1: 230-233.</li>
<a name="51"></a><li value="51">Hofman J., Cetron M.S., Farley M.M., et al. The prevalence of drug-resistant <i>Streptococcus pneumoniae</i> in Atlanta. N.Engl.J.Med., 1995, 333: 481-486.</li>
<a name="52"></a><li value="52">Nakae M., Murai T., Kaneko Y., et al. Drug resistance in <i>Streptococcus pyogenes</i> isolated in Japan in (1974-1975). Antimicrob. Agents Chemother., 1977, 12: 427-428.</li>
<a name="53"></a><li value="53">Seppala H., Nissinen A., Jarvinen H., et al. Resistance to erythromycin in group A streptococci. N. Engl. J. Med., 1992, 326: 292-297.</li>
<a name="54"></a><li value="54">Seppala H., Klaukka T., Lehtonen R., et al. Erythromycin resistance of group A streptococci from throat samples is related to age. Pediatr. Infect. Dis. J., 1997, 16: 651-656.</li>
<a name="55"></a><li value="55">Seppala H., Klaukka T., Vuopio-Varcila J., et al. The effect of changes of the consumption of macrolide antibiotics on erythromycin resistance in group A streptococci in Finland. N.&nbsp;Engl. J.&nbsp;Med., 1997, 337: 441-446.</li>
<a name="56"></a><li value="56">Seppala H., Nissinen A., Yu Q., et al. Three different phenotypes of erythromycin-resistant <i>Streptococcus pyogenes</i> in Finland, J. Antimicrob. Chemother., 1993, 32: 885-891.</li>
<a name="57"></a><li value="57">Cayla R., Zerbib F., Talbi P., et al. Pre- and post-treatment clarithromycin resistance of <i>Helicobacter pylori</i> strains: a key factor of treatment failure. Gut, 1995, 37 (suppl.&nbsp;1): A55.</li>
<a name="58"></a><li value="58">Shah P.M., Bryskier A. Epidemiology of resistance to macrolide antibiotics. In: Macrolides. Bryskier&nbsp;A.J., Butzler&nbsp;J.P., Neu&nbsp;H.C., Tulkens&nbsp;P.M. (Eds.). Paris, 1993: 143-166.</li>
<a name="59"></a><li value="59">Heifets L., Mor N., Vandekolk J. <i>Mycobacterium avium</i> strains resistant to clarithromycin and azithromycin, Antimicrob. Agents Chemother., 1993, 37: 2364-2370.</li>
<a name="60"></a><li value="60">Craig W.A., Gudmundson S. Postantibiotic effect. In: Antibiotics in Laboratory Medicine. Lorian&nbsp;V. (Ed.). Baltimore etc., 1996: 403-431.</li>
<a name="61"></a><li value="61">Bergogne-Berezin E. Clinical significance of studies on antibiotic concentrations in the lower respiratory tract. In: Predicting Antibiotic Response in Respiratory Tract Infections. Highlights from the 7th International Congress for Infectious Diseases. Hong&nbsp;Kong, 1996: 7-8.</li>
<a name="62"></a><li value="62">Odenholt-Tornqvist I., Lowdin E., Cars 0. Postantibiotic effects and postantibiotic sub-MIC effects of roxithromycin, clarithromycin, and azithromycin on respiratory tract pathogens. Antimicrob. Agents Chemother., 1995, 39: 221-226.</li>
<a name="63"></a><li value="63">Fang G.D., Stout J.E., Yu V.L, Comparison of intracellular postantibiotic effect of azithromycin and clarithromycin vs. erythromycin against Legionella pneumophila serogroup 1. In: The 36th International Conference on Antimicrobial Agents and Chemotherapy, New Orleans, 1996; abstr. A91.</li>
<a name="64"></a><li value="64">Dubois J., Saint-Pierre C. Post antibiotic effect and bactericidal activity of clarithromycin against <i>Heamophilis, Streptococcus</i> and <i>Moraxella</i> strains isolated from maxillary sinus aspiration. In: The 20th International Congress of Chemotherapy. Sydney, 1997: abstr. 2203.</li>
<a name="65"></a><li value="65">Fuursted K., Knudsen J.D., Petersen M.B., et al. Comparative study of bactericidal activities, postantibiotic effects and effects on bacterial virulence of penicillin G and six macrolides against <i>Streptococcus&nbsp;pneumoniae</i>. Antimicrob. Agents Chemother., 1997, 41: 781-784.</li>
<a name="66"></a><li value="66">Hirakata Y., Kaku M., Tomono K., et al. Efficacy of erythromycin lactobionate for treating <i>Pseudomonas aeruginosa</i> bacteriemia in mice. Antimicrob. Agents Chemother., 1992, 36: 1198-1203.</li>
<a name="67"></a><li value="67">Kita E., Sawaki M., Misaka K., et al. Immunomodulatory effects of roxithromycin in mice. In: The 17th International Congress of Chemotherapy. Berlin, 1991: abstr. 765.</li>
<a name="68"></a><li value="68">Tateda K., Ishii Y., Matsumoto T., et al. New evidence of antipseudomonal activity of macrolides. In: The 36th Interscience Conference of Antimicrobial Agents and Chemotherapy. New Orleans, 1996: abstr. C82.</li>
<a name="69"></a><li value="69">Tateda K., Ishii Y., Matsumoto T., et al. Direct evidence for antipseudomonal activity of macrolides; exposure-dependent bactericidal activity and inhibition of protein synthesis by erythromycin, clarithromycin, and azithromycin. Antimicrob. Agents Chemother., 1996, 40: 2271-2275.</li>
<a name="70"></a><li value="70">Labro M.T., Amit N., Babin-Chevaye C., et al. Synergy between RU 28965 (roxithromycin) and human neutrophils for bactericidal activity <i>in&nbsp;vitro</i>. Antimicrob. Agents Chemother., 1986, 30: 137-142.</li>
<a name="71"></a><li value="71">Labro M.T., Babin-Chevaye C. Synergistic interaction of josamycin with human neutrophils bactericidal function <i>in&nbsp;vitro</i>. J.&nbsp;Antimicrob. Chemother., 1989, 24: 731-740.</li>
<a name="72"></a><li value="72">Horn W., Jantzen R., Lucke J. Determination of intracellular antibacterial activity of antibiotics by means of a fluorochrome microassay. In:
The Influence of Antibiotics on the Host-Parasite Relationship, vol. III. Gillissen G., Opferkuch W., Peters G., Pulverer G. (Eds.). Berlin, 1989: 152-159.</li>
<a name="73"></a><li value="73">Moore L., Summers P., Humbert J., et al. Synergisrn between azithromycin and TNF-primed PMNs in cidal activity against Chlamidia. In: The 30th Interscience Conference on Antimicrobial Agents and Chemotherapy. Atlanta, 1990: abstr. 157.</li>
<a name="74"></a><li value="74">Labro M.T., El Benna J., Abdelghaffar H. Modulation of human polymorphonuclear neutrophil function by macrolides: preliminary data concerning dirithromycin. J.&nbsp;Antimicrob. Chemother., 1993, 31 (suppl.&nbsp;C): 51-64.</li>
<a name="75"></a><li value="75">Labro M.T., Abdelghaffar H., Bryskier A. L-cladinose is involved in the antioxidant and degranulating effect of erythromycin A-derived macrolides. In: The 36th International Conference on Antimicribial Agents and Chemotherapy. New&nbsp;Orleans, 1996: abstr. G22.</li>
<a name="76"></a><li value="76">Labro M.T. Intracellular bioactivity of macrolides. Clin. Microbiol. Infect., 1996, 1 (suppl. 1): S24-30.</li>
<a name="77"></a><li value="77">Gemmell C.G. Macrolides and host defences to respiratory tract pathogens. J.&nbsp;Hosp. Infect., 1991, 19 (suppl.&nbsp;A): 11-19.</li>
<a name="78"></a><li value="78">McDonald P.J., Pruul H. Macrolides and the immune system. Scand. J.&nbsp;Infect. Dis., 1992, 83 (suppl. 1): 34-40.</li>
<a name="79"></a><li value="79">Van den Broek P.J., Bril-Bazuin C., Mattie H. Antibacterial activity of defensins against <i>Staphylococcus aureus</i> pretreated with benzylpenicillin or azithromycin. In: The 36th International Conference on Antimicrobial Agents and Chemotherapy. New&nbsp;Orleans, 1996: abstr. C88.</li>
<a name="80"></a><li value="80">Tarayre J.P., Aliaga M., Barbara M., et al. Cutaneously applied erythromycin base reduces various types of inflammatory reaction in mouse ear. Int. J.&nbsp;Tissue React., 1987, 9: 77-85.</li>
<a name="81"></a><li value="81">Misaka K., Kita E., Sawaki M., et al. The antiinflammatory effect of erythromycin in zimozan induced peritonitis of mice. J.&nbsp;Antimicrob. Chemother., 1992, 30: 339-348.</li>
<a name="82"></a><li value="82">Miyatake H., Taki F., Taniguchi H., et al. Erythromycin reduces the severity of bronchial hyperresponsiveness in asthma. Chest, 1991, 99: 670-673.</li>
<a name="83"></a><li value="83">Tsang K.W.T., Ho P.L., Ho C.S., et al. Low dose erythromycin is highly efficacious in patients with active bronchiectasis. In: European Respiratory Society. Annual Congress. Berlin, 1997: abstr. 740.</li>
<a name="84"></a><li value="84">Agen C., Danesi R., Blandizzi C., et al. Macrolide antibiotics as antiinflammatory agents: roxithromycin in an unexpected role. Agents Action, 1993, 38: 85-90.</li>
<a name="85"></a><li value="85">Scaglione F., Rossini G. Comparative antiinflammatory effect of roxithromycin, azithromycin and clarithromycin. In: The 3rd International Conference on the Macrolides, Azalides and Streptogramins, Lisbon, 1996: abstr. 9.04.</li>
<a name="86"></a><li value="86">Black P.N. The use of macrolides in the treatment of asthma. Eur.
Respir, Rev., 1996, 6: 240-243.</li>
<a name="87"></a><li value="87">Bryskier A., Agouridas C., Chantot J.F. New insights into the structure-activity relationship of macrolides and azalides. In: New Macrolides, Azalides, and Streptogramins in Clinical Practice. Neu&nbsp;H.C., Young&nbsp;L.S., Zinner&nbsp;S.H., Acar&nbsp;J.F. (Eds.). New&nbsp;York, etc., 1995: 3-30.</li>
<a name="88"></a><li value="88">Sugiyama Y., Kitamura S., Kasahara T. Cytokines production from alveolar macrophages of rats fed by long term, low dose erythromycin. In: European Respiratory Society. Annual Congress. Berlin, 1997: abstr. P0432.</li>
<a name="89"></a><li value="89">Hori S., Sato J., Kawamura M. Macrolides increase endogenous glucocrticoid levels. In: The 36th Conference on Antimicrobial Agents and Chemotherapy. New&nbsp;Orleans, 1996: abstr. A83.</li>
<a name="90"></a><li value="90">Kobayashi 0., Ohtani H., Nagino K.., et al. Immunologic manifestation and therapeutic possibilities of macrolides in diffuse panbronchiolitis. In: The 3rd International Conference on the Macrolides, Azalides and Streptogramins. Lisbon, 1996: abstr. 9.07.</li>
<a name="91"></a><li value="91">Catnach S.M., Fairclough P.D. Erythromycin and the gut. Gut, 1992,
33: 397-401.</li>
<a name="92"></a><li value="92">Janssens J., Peeters T.L., Vantrappen G., et al. Improvement of gastric emptying in diabetic gastroparesis be erythromycin. N.&nbsp;Engl. J.&nbsp;Med.,
1990, 322: 1028-1031.</li>
<a name="93"></a><li value="93">Bergan T. Pharmacokinetics of newer macrolides. In: New Macrolides, Azalides, and Streptogramins in Clinical Practice. Neu&nbsp;H.C., Young&nbsp;L.S., Zinner&nbsp;S.H., Acar&nbsp;J.F. (Eds.). New&nbsp;York, etc., 1995: 51-60.</li>
<a name="94"></a><li value="94">Guay D.R.P. Macrolide antibiotics in pediatric infectious diseases. Drugs, 1996, 51: 515-536.</li>
<a name="95"></a><li value="95">Nilsen 0. Comparative pharmacokinetics of macrolides. J.&nbsp;Antimicrob. Chemother., 1987, 20 (suppl.&nbsp;B): 81-88.</li>
<a name="96"></a><li value="96">Periti P., Mazzei T., Mini E., et al. Pharmacokinetic drug interactions of macrolides. Clin. Pharmacokinet., 1992, 23: 106-131.</li>
<a name="97"></a><li value="97">Haviland J.W. Anvances in antibiotic therapy. Ann. Int. Med., 1953, 39: 307-317.</li>
<a name="98"></a><li value="98">Downey K.M., Chaput de Saintonge D.M. Gastrointestinal side effects after intravenous erythromycin lactobionate. Br. J.&nbsp;Clin. Pharmacol, 1986, 21: 295-299.</li>
<a name="99"></a><li value="99">Zulkifli, Fachr H., Efiaty S., et al. A comparative study of spiramycin and erythromycin in acute tonsillopharyngitis. Curr. Med, Res. Opin., 1984. 8: 708-713.</li>
<a name="100"></a><li value="100">Sefton A.M., Maskell J.P., Kerawala C., et al. Comparative efficacy and tolerance of erythromycin and josamycin in the prevention of bacteriemia following dental extraction. J.&nbsp;Antimicrob. Chemother., 1990, 25: 975-984.</li>
<a name="101"></a><li value="101">Norrby S.R. Safety and drug-drug interactions of macrolides, azalides, and streptogramins. In; New Macrolides, Azalides, and Streptogramins in Clinical Practice. Neu&nbsp;H.C., Young&nbsp;L.S., Zinner&nbsp;S.H., Acar&nbsp;J.F. (Eds.). New&nbsp;York, etc., 1995: 61-69.</li>
<a name="102"></a><li value="102">Zara G., Qin X.Y., Pilot M.A., et al. Response of the human gastrointestinal tract to erythromycin. J.&nbsp;Gastrointest. Motil., 1991, 3: 26-31.</li>
<a name="103"></a><li value="103">Sifrim D., Janssens J., Vantrappen G, Effect of midecamycin acetate on gastrointestinal motility in humans. Int. J.&nbsp;Clin, Pharm., 1992, 12: 71-79.</li>
<a name="104"></a><li value="104">Nakayoshi T., Izumi M., Tatsuta K. Effects of macrolide antibiotics on gastrointestinal motility in fasting and digestive states. Drugs Exptl. Clin. Res., 1992, 18: 103-109.</li>
<a name="105"></a><li value="105">Peeters T.L., Matthys G., Depootere I., et al. Erythromycin is a motilin receptor agonist. Am- J.&nbsp;Physiol., 1989, 257: 470-474.</li>
<a name="106"></a><li value="106">Depootere I., Peeters T.L., Matthys G., et al. Structure activity relation of erythromycin-related macrolides in inducing contractions and in displacing bound motilin in rabbit duodenum. J.&nbsp;Gastrointest. Motil., 1989, 1: 150-159.</li>
<a name="107"></a><li value="107">Tomomasa T., Kuruome T., Arai H., et al. Erythromycin induces migrating motor complex in human gastrointestinal tract. Digest. Dis. Sci., 1986, 31: 157-161.</li>
<a name="108"></a><li value="108">Descotes J. Chemical structures and safety of spiramycin. Drug Invest., 1993, 6 (suppl. 1): 43-48.</li>
<a name="109"></a><li value="109">Brummett R.E. Ototoxic liability of erythromycin and analogues. Otolaryngol. Clin. North. Am., 1992, 26; 811-819.</li>
<a name="110"></a><li value="110">Stein G.E., Havlichek D.H. The new macrolide antibiotics.Postgrad. Med., 1992, 269-282.</li>
<a name="111"></a><li value="111">Hopkins S. Clinical toleration and safety of azithromycin. Am. J.&nbsp;Med., 1991, 91 (suppl.&nbsp;3A): 40-45.</li>
<a name="112"></a><li value="112">Craft J.C., Siepman N. Overview of the safety profile of clarithromycin suspension in pediatric patients. Pediatr. Infect. Dis.&nbsp;J., 1993, 12: 142-147.</li>
<a name="113"></a><li value="113">Fraschini F. Clinical efficacy and tolerance of two new macrolides, clarithromycin and josamycin, in the treatment of patients with acute exacerbations of chronic bronchitis. J.&nbsp;Int. Med. Res., 1990, 18: 171-176.</li>
<a name="114"></a><li value="114">Straneo G., Scarpazza G, Efficacy and safety of clarithromycin versus josamycin, in the treatment of hospitalized patients with bacterial pneumonia. J.&nbsp;Int. Med. Res., 1990, 18: 164-170.</li>
<a name="115"></a><li value="115">Gendrel D., Bourrillon A., Bingen E., et al. Five-day spiramycin vs. seven-day penicillin V in the treatment of streptococcal tonsillitis in children. Clin. Drug. Invest., 1997. 13: 338-344.</li>
<a name="116"></a><li value="116">Treadway G., Pontani D. Paediatric safety of azithromycin; worldwide experience. J.&nbsp;Antimicrob. Chemother., 1996. 37 (suppl.&nbsp;C): 143-149.</li>
<a name="117"></a><li value="117">Markham A., Faulds D. Roxithromycin: an update of its antimicrobial activity, pharmacokinetic properties and therapeutic use. Drugs, 1994, 48: 297-326.</li>
<a name="118"></a><li value="118">Periti P., Mazzei T., Mini E., et al. Adverse effects of macrolide antibacterials. Drug Saf., 1993, 9: 346-364.</li>
<a name="119"></a><li value="119">Jacobs R.F., Schutze G.E., Young R.A., et al. Antimicrobial agents. In: Principles and Practice of Pediatric Infectious Diseases. Long S.S.,Pickering L.K., Prober C.G. (Eds.). New York, etc., 1997: 1604-1662.</li>
<a name="120"></a><li value="120">Cisapride drug interactions can be fatal. Drugs Therap. Perspect., 1997, 9: 11-13.</li>
<a name="121"></a><li value="121">Latare P.A., Setness P.A. Using erythromycin. Postgrad. Med., 1989, 86: 55-63.</li>
<a name="122"></a><li value="122">Rodvold K.A., Piscitelli S.C. New oral macrolide and fluoroquinolone antibiotics: an overview of pharmacokinetics, interactions, and safety. Clin. Infect. Dis., 1993, 17 (suppl.&nbsp;1): 192-199.</li>
<a name="123"></a><li value="123">Zinner S.H. Macrolides and streptogramins. In: Current Infectious Disease Drugs. Andriole V.T. (Ed.), 1st ed. Philadelphia, 1995: 139-147.</li>
<a name="124"></a><li value="124">McCarty J.M., Guthrie E.H., Huck W., et al. Dirithromycin versus erythromycin base in streptococcal pharyngitis/tonsillitis. In: The 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy. Los Angeles, 1992: abstr. 1673.</li>
<a name="125"></a><li value="125">Still J.G., Palmer R. An evaluation of clarithromycin and penicillin in patients with streptoooccal pharyngitis. In: The 2th International Conference on the Macrolides, Azalides and Streptogramins. Venice, 1994: abstr. 240.</li>
<a name="126"></a><li value="126">Schito G.C., Pesce A., Marchese A. The role of macrolides in <i>Streptococcus pyogenes</i> pharyngitis. J. Antimicrob. Chemother., 1997, 39:
562-565.</li>
<a name="127"></a><li value="127">Jackson M.A., Burry V.F., Olson L.C., et al. Breakthrough sepsis in macrolide-resistant pneumococcal infection. Pediatr. Infect. Dis.&nbsp;J., 1996, 15: 1049-1051.</li>
<a name="128"></a><li value="128">Reid J.R., Bradley J.S., Hindler J. Pneumococcal meningitis during therapy for otitis media with clarithromycin. Pediatr. Infect. Dis.&nbsp;J., 1995, 14: 1104-1105.</li>
<a name="129"></a><li value="129">Dagan R., Leibowitz E., Jacobs M., et al. Bacteriologic response to acute otitis media caused by <i>Haemophilus influenzae</i> treated with azithromycin. In: The 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, 1997: abstr. K-102.</li>
<a name="130"></a><li value="130">Falck G., Engstrand I., Gnarpe J., et al. <i>Chlamydia pneumoniae</i> in otitis media. In: The 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, 1997: abstr. K-109.</li>
<a name="131"></a><li value="131">Gwaltney J.M. Acute bronchitis. In: Princeples and Practice of Infectious Diseases. 4th ed. Mandell&nbsp;G.L., Bennett&nbsp;J.E., Dolin&nbsp;R. (Eds.). New&nbsp;York, etc., 1995; 606-608.</li>
<a name="132"></a><li value="132">Charles L., Segreti J. Choosing the right macrolide antibiotic: a guide to selection. Drugs, 1997, 53: 349-357.</li>
<a name="133"></a><li value="133">Dark D. Multicenter evaluation of azithromycin and cefaclor in acute lower respiratory tract infections. Am. J.&nbsp;Med., 1991, 91 (suppl.&nbsp;3A): 31-35.</li>
<a name="134"></a><li value="134">Aldons P.M. A comparison of clarithromycin and ampicillin in the treatment of outpatients with acute bacterial exacerbation of chronic bronchitis. J.&nbsp;Antimicrob. Chemother., 1991, 27 (suppl. A): 101-108.</li>
<a name="135"></a><li value="135">Karalus N.C., Garrett J.E., Lang S.D.R., et al, A clinical and economic comparison of roxithromycin 150 mg twice daily vs. amoxicillin 500 mg/clavulanic acid 125 mg three times daily for the treatment of lower respiratory tract infections in general practice. Drug. Invest., 1994,
8: 179-190.</li>
<a name="136"></a><li value="136">Gotfried M H. Macrolide use in the treatment of lower respiratory tract infections. Infect. Dis. Clin. Pract., 1995, 4: 349-358.</li>
<a name="137"></a><li value="137">Ramirez J.A., Ahkee S. Early switch from intravenous antimicrobials to oral clarithromycin in the treatment of hospitalized patients with community-acquired pneumonia. In: The 3rd International Conference on the Macrolides, Azalides and Streptogramins. Lisbon, 1996: abstr. 12.04.</li>
<a name="138"></a><li value="138">American Thoracic Society. Medical section of the Amirican Lung Association. Guidelines for the initial management of adults with community-acquired pneumonia: diagnosis, assessment of severity, and initial antimicrobial therapy. Am. Rev. Respir. Dis., 1993, 148: 1418-1426.</li>
<a name="139"></a><li value="139">Edelstein P.H. Legionnaires' disease. Clin. Infect. Dis., 1993, 16:
741-749.</li>
<a name="140"></a><li value="140">Modai J. The clinical use of macrolides. J.&nbsp;Antimicrob. Ghemother., 1988, 22 (suppl. B): 145-153.</li>
<a name="141"></a><li value="141">Aoyama T., Sunakawa K., Iwata S., et al. Efficacies of shortterm treatments of pertussis by clarithromycin and azithromycin; comparisons with the standart regimen by erythromycin. In: The 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. San&nbsp;Francisco, 1995: abstr. LM48.</li>
<a name="142"></a><li value="142">Amaya-Tapia G., Aguirre-Avalos G., Andrade-Vilianueva J., et al. Once-daily azithromycin in the treatment of adult skin and skin-structure infections. J.&nbsp;Antimicrob. Chemother., 1993, 31 (suppl.&nbsp;E): 129-135.</li>
<a name="143"></a><li value="143">Rodriguez-Solarez A., Perez-Gutierrez F., Prosperi J., et al. A comparative study of the efficacy, safety and tolerance of azithromycin, dicloxacillin and flucloxacillin in the treatment of children with acute skin and skin-structure infections. J.&nbsp;Antimicrob. Chemother., 1993, 31 (suppl.&nbsp;E): 103-109.</li>
<a name="144"></a><li value="144">Centers for Disease Control (CDC) Report. Recommendations for the prevention and management of <i>Chlamydia trachomatis</i> infections, 1993. MMWR, 1993, 42 (RR-12): 27-28.</li>
<a name="145"></a><li value="145">Bowie W.R. Urethritis and infections of the lower urogenital tract.
Urol. Clin. North Am., 1980, 7: 17-21.</li>
<a name="146"></a><li value="146">Bowie W.R. Epidemiology and therapy of <i>Chlamydia trachomatis</i>
infections. Drugs, 1984, 27: 459-468.</li>
<a name="147"></a><li value="147">Mashkilleyson A.L., Gomberg M.A., Mashkilleyson N., et al. Treatment of syphilis with azithromycin. Int: J.&nbsp;STD & AIDS, 1996, 7 (suppl. 1): 13-15.</li>
<a name="148"></a><li value="148">Handsfield H.H. Sexually transmitted chlamydial infections, gonorrhoea and syphilis. In: New Macrolides, Azalides, and Streptogramins. Neu&nbsp;H.C., Young&nbsp;L.S., Zinner&nbsp;S.H. (Eds.). New&nbsp;York, 1993: 167-172.</li>
<a name="149"></a><li value="149">Waugh M.A. Open study of the safety and efficacy of a single oral dose of azithromycin for the treatment of uncomplicated gonorrhoea in men and women. J.&nbsp;Antimicrob. Chemother., 1993, 31 (suppl. E): 193-198.</li>
<a name="150"></a><li value="150">Francois A., Carli-Basset C. Treatment of acute gonococcal urethritis. Sci. Med., 1973, 4: 67-70.</li>
<a name="151"></a><li value="151">Ancelle G. Infectious lesions of the vulva. Contracept. Fertil. Sex.,
1978, 6: 663-668.</li>
<a name="152"></a><li value="152">Mandal B.K.., Ellis M.E., Dunbar E.M., et al. Double-blind placebo-
controlled trial of erythromycin in the treatment of clinical campylobacter infection. J.&nbsp;Antimicrob. Chemother., 1984, 13: 619-623.</li>
<a name="153"></a><li value="153">Salazar-Lindo E.R., Sack R.B.. Chea-Woo E., et al. Early treatment with erythromycin of <i>Campylobacter jejuni</i>-associated dysentery in children. J.&nbsp;Pediatr., 1986, 109: 355-360.</li>
<a name="154"></a><li value="154">Gorbach S.L. Bacterial diarrhoea and its treatment. Lancet, 1987, ii. 1378-1382.</li>
<a name="155"></a><li value="155">Kuschner R.A., Trofa A.F., Thomas R.J., et al. Use of azithromycin for the treatment of Campylobacter enteritis in travelers to Thailand, an area where ciprofloxacin resistance is prevalent. Clin. Infect. Dis., 1995, 21: 536-541</li>
<a name="156"></a><li value="156">Portnoy D., Whiteside M.E., Buckley E., et al. Treatment of intestinal cryptosporidiosis with spiramycin. J.&nbsp;Antimicrob. Chemother., 1985, 16 (suppl. A): 167-173.</li>
<a name="157"></a><li value="157">Moskovitz B.L., Stanton T.L., Kusmierek J.J.E. Spiramycin therapy for cryptosporidial diarrhoea in immunocompromised patients. J.&nbsp;Antimicrob. Chemother., 1988, 22 (suppl. B): 189-191.</li>
<a name="158"></a><li value="158">Saez-Llorens X., Odio C.M., Umana M.A., et al. Spiramycin vs. placebo for treatment of acute diarrhea caused by <i>Cryptosporidium</i>. Pediatr. Infect. Dis., 1989, 8: 136-140.</li>
<a name="159"></a><li value="159">Sprinz E. AIDS-related cryptosporidium diarrhea: a pilot study with roxithromycin. In: The 3rd International Conference on the Macrolides, Azalides and Streptogramins. Lisbon, 1996: abstr. 7.26.</li>
<a name="160"></a><li value="160">Desmonts G., Couvreur J. Congenital toxoplasmosis: a prospective study of 378 pregnancies. N.&nbsp;Engl. J.&nbsp;Med., 1974, 290: 1110-1116.</li>
</ol>

<br>
<!--counters-->
<table border="0" cellpadding="0" cellspacing="5" width="100%">
<tr>
  <td align="left" valign="bottom" style="vertical-align:bottom;"><font class="t8">&copy; 2000-2007 <a target="_blank" href="../../copyright.php.html">НИИАХ СГМА</a></font></td>
  <td align="right">
<!--Rambler 1x1--><a href="http://top100.rambler.ru/top100/"><img src="../../top100.cnt.gif?335834" alt="Rambler's Top100" width="1" height="1" border="0"></a><!--/Rambler 1x1-->

<!--TopList--><a target="_top" href="http://top.list.ru/jump?from=96637"><img src="../../counter-1.gif?id=96637;t=58" border="0" height="31" width="88" alt="TopList"></a><!--/TopList-->

<!--Rambler--><a href="http://top100.rambler.ru/top100/" target="_blank"><img src="../../top100/banner-88x31-rambler-darkblue2.gif" alt="Rambler's Top100" width="88" height="31" border="0"></a><!--/Rambler-->

<br><!--RAX--><script language="JavaScript"><!--
document.write('<a href="http://www.rax.ru/click" '+
'target=_blank><img src="http://counter.yadro.ru/hit?t26.11;r'+
escape(document.referrer)+((typeof(screen)=='undefined')?'':
';s'+screen.width+'*'+screen.height+'*'+(screen.colorDepth?
screen.colorDepth:screen.pixelDepth))+';'+Math.random()+
'" alt="rax.ru: показано число посетителей за сегодн\я" '+
'border=0 width=88 height=15></a>')//--></script><!--/RAX-->
  </td>
</tr>
</table>
<!--/counters-->

</body>
</html>
